v3.26.3
COLLABORATIONS - Schedule of Revenue Recognized under Collaboration (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized $ 1,458,086 $ 1,249,026 $ 3,916,209 $ 2,616,904
Regeneron Pharmaceuticals        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized 32,334 22,542 83,690 106,123
Regeneron Pharmaceuticals | Research Services Obligation | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized 7,345 12,540 13,176 39,306
Regeneron Pharmaceuticals | C5 License Obligation | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized 0 0 0 21,370
Regeneron Pharmaceuticals | Regeneron Technology Transfer Obligation | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized 0 0 0 2,431
Regeneron Pharmaceuticals | Other license programs | Global Strategic Collaboration        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Revenue recognized $ 24,989 $ 10,002 $ 70,514 $ 43,016